Multivalent biological toxin antigen vaccine based on dual receptor binding domain (RBD) assembly and preparation method and application thereof

By using genetic engineering technology to prepare a multivalent biological toxin vaccine with dual Hc fusion proteins, the problem of existing vaccines being unable to protect against multiple biological toxins has been solved, achieving broad-spectrum protection against multiple toxins and safe and efficient vaccine preparation.

CN116270998BActive Publication Date: 2026-07-24ACADEMY OF MILITARY MEDICAL SCIENCES
6 Cites 0 Cited by

Patent Information

Application Number
CN202310247930.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-15
Publication Date
2026-07-24
Estimated Expiration
2043-03-15

AI Technical Summary

Technical Problem

Existing botulinum toxin and tetanus toxin vaccines cannot effectively protect against a variety of biological toxins, and traditional vaccine production processes are not safe or efficient enough to cope with the variability of toxins with multiple serotypes and subtypes.

Method used

By fusing the Hc antigens of the receptor-binding regions of different biotoxins using genetic engineering techniques, a double Hc fusion protein is prepared as a multivalent biotoxin vaccine. The highly efficient fusion protein is obtained by expressing and purifying it using recombinant Escherichia coli, and then an adjuvant is added to prepare a multivalent biotoxin molecular antigen vaccine.

Benefits of technology

It achieves broad-spectrum protection against a variety of biological toxins, improves the safety and efficacy of vaccines, and can simultaneously prevent multiple biological toxin pathogens, especially botulinum toxins of types A, B, E, F and H, as well as tetanus toxin.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application discloses a multivalent biological toxin antigen vaccine based on double receptor binding domain (RBD) assembly and a preparation method and application thereof. The application provides a multivalent biological toxin molecular antigen vaccine, and an active ingredient of the vaccine is a fusion protein formed by connecting an Hc protective antigen of biological toxin 1 and an Hc protective antigen of biological toxin 2 through a connecting peptide; the biological toxin 1 and the biological toxin 2 are two different biological toxins; and the biological toxin is selected from the following: tetanus toxin or other types of botulinum toxin (including types A, B and H) except type E. The application proves that different serotypes of botulinum toxin and tetanus toxin receptor binding domain Hc antigens are fused and assembled into a double Hc fusion antigen molecule by using genetic engineering and biosynthesis technology, and the double Hc fusion antigen molecule can generate strong protection against multiple biological toxins as a single subunit vaccine. Therefore, the Hc fusion antigen molecule vaccine of the application can generate protection against multiple different serotypes of biological toxin pathogens, and can be used as a broad-spectrum multivalent vaccine for biological toxin prevention and preventive treatment.
Need to check novelty before this filing date? Find Prior Art